Sarissa Capital Acquisition Corp.
| General Information | |
| Business: | It is our intention to pursue prospective targets that are focused on health care and biopharma. Sarissa will target businesses with valuations of $500 million to $1 billion that have the potential to be substantially greater over time due to their underlying business characteristics and growth opportunities as a public company. Our focus will be on the health-care industry in the United States and other developed countries. Alexander Denner, Ph.D., serves as the chairman and CEO of Sarissa Capital Acquisition Corp. Our sponsor is an affiliate of Sarissa Capital Management LP, a leading health-care and biopharma investment firm. Sarissa was founded in 2013 by Alexander Denner, Ph.D., the firm’s CEO and chief investment officer, following a successful nearly two-decade career as a health-care investor at Morgan Stanley, Icahn Capital and Viking Capital.
|
| Industry: | BLANK CHECKS |
| Employees: | 0 |
| Founded: | 2020 |
| Contact Information | |
| Address | 660 Steamboat Rd Greenwich, CT 06830 |
| Phone Number | 203-302-2330 |
| Web Address | |
| View Prospectus: | Sarissa Capital Acquisition Corp. |
| Financial Information | |
| Market Cap | $218.75mil |
| Revenues | $0 mil (last 12 months) |
| Net Income | $0 mil (last 12 months) |
| IPO Profile | |
| Symbol | SRSAU |
| Exchange | NASDAQ |
| Shares (millions): | 17.5 |
| Price range | $10.00 - $10.00 |
| Est. $ Volume | $175.0 mil |
| Manager / Joint Managers | Cantor Fitzgerald |
| CO-Managers | |
| Expected To Trade: | 10/21/2020 |
| Status: | Priced |
| Quiet Period Expiration Date: | Available only to Subscribers |
| Lock-Up Period Expiration Date: | Available only to Subscribers |
| SCOOP Rating | Available only to Subscribers |
| Rating Change | Available only to Subscribers |